TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27916480

Group type: EXPERIMENTAL
Intervention: A1 proteinase inhibitor (A1PI) treatment (60 mg/kg per week)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Delayed-start group (placebo)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Delayed-start group (after 24 months)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Early-start group (after 24 months)
Number of subjects: 140
Study: 25408261

Group type: EXPERIMENTAL
Intervention: Pomelo pulp (250g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (250mL)
Number of subjects: 0
Study: 24627921

Group type: EXPERIMENTAL
Intervention: Restricted intravenous fluid regimen (R group)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard fluid regimen (S group)
Number of subjects: 174
Study: 20933512

Group type: EXPERIMENTAL
Intervention: High-flavonol diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-flavonol diet
Number of subjects: 17
Study: 18182544

Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional vocational rehabilitation program
Number of subjects: 92
Study: 16645442

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at the rate of 1-8 mug . kg . min for 15-20 min
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Approximate entropy (ApEn)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Parietal montages
Number of subjects: 28
Study: 12965108

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg t.i.d. for 16 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10907674

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 100 mg)
Number of subjects: 44
Study: 8836952

Group type: EXPERIMENTAL
Intervention: 0.1 mg melatonin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.0 mg melatonin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5.0 mg melatonin
Number of subjects: 32

Group type: COMPARATOR
Intervention: sucrose placebo
Number of subjects: 32
Study: 1317939

Group type: EXPERIMENTAL
Intervention: 5 micrograms/min human alpha atrial natriuretic factor (h alpha ANF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6

Group type: COMPARATOR
Intervention: 3 IU AVP
Number of subjects: 6
Study: 6438674

Group type: EXPERIMENTAL
Intervention: Diazepam (Valium) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31484076

Group type: EXPERIMENTAL
Intervention: β-glucan trained monocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-32 expression
Number of subjects: 0
Study: 29469177

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion (24 hours)
Number of subjects: 23
Study: 26500107

Group type: EXPERIMENTAL
Intervention: Surfactant (calfactant/Infasurf)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Sham instillation
Number of subjects: 511
Study: 24758641

Group type: EXPERIMENTAL
Intervention: Delayed oocyte maturation trigger (24 hours later) in patients with low progesterone (<= 1 ng/ml)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (same day trigger) in patients with low progesterone (<= 1 ng/ml)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Delayed oocyte maturation trigger (24 hours later) in patients with elevated progesterone (> 1 ng/ml)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (same day trigger) in patients with elevated progesterone (> 1 ng/ml)
Number of subjects: 131
Study: 23460253

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Film dressing
Number of subjects: 289

Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 289
Study: 20435234

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Entecavir 0.5 mg
Number of subjects: 131
Study: 19040944

Group type: EXPERIMENTAL
Intervention: Strict definition of perforation (a hole in the appendix or a fecalith in the abdomen)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nonperforated appendicitis (treated as nonperforated)
Number of subjects: 131
Study: 16630123

Group type: EXPERIMENTAL
Intervention: Concurrent R-CHOP (6 courses of CHOP concurrently with rituximab)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sequential R-CHOP (6 courses of CHOP followed by 6 courses of weekly rituximab)
Number of subjects: 69
Study: 14649479

Group type: EXPERIMENTAL
Intervention: Detection of minimal residual disease (MRD) by identifying clone-specific T-cell receptor (TCR) or immunoglobulin (Ig) gene rearrangements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of residual disease at defined timepoints by cytomorphology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized tools for treatment response evaluation
Number of subjects: 0
Study: 11298086

Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9674365

Group type: EXPERIMENTAL
Intervention: Fecal occult blood screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removal of benign polyps larger than 9 mm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy
Number of subjects: 0
Study: 7939995

Group type: EXPERIMENTAL
Intervention: Cotrel-Dubousset instrumentation (CDI) with instrumentation/fusion of the proximal thoracic curve up to T2 in Group I patients.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cotrel-Dubousset instrumentation (CDI) without instrumentation/fusion of the upper thoracic curve in Group II patients.
Number of subjects: 54
Study: 3283229

Group type: EXPERIMENTAL
Intervention: High calcium intake (1400 mg/day: 400‐mg calcium diet plus two 500‐mg calcium tablets/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low calcium intake (400 mg calcium diet plus two placebo tablets/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low calcium intake
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High calcium intake
Number of subjects: 15
Study: 31436886

Group type: EXPERIMENTAL
Intervention: Daily naltrexone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 27340247

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 456
Study: 26351344

Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus capecitabine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo plus capecitabine
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus capecitabine (in patients with inflammation)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo plus capecitabine (in patients with inflammation)
Number of subjects: 127
Study: 23369075

Group type: EXPERIMENTAL
Intervention: Exercise training (supervised exercise training twice weekly for eight weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care (weekly telephone support)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 116
Study: 21815740

Group type: EXPERIMENTAL
Intervention: Positive message framing
Number of subjects: 188

Group type: COMPARATOR
Intervention: Negative message framing
Number of subjects: 188
Study: 19168349

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500mg/m² (Pem500)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Pemetrexed 900mg/m² (Pem900)
Number of subjects: 102
Study: 16461201

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 812

Group type: COMPARATOR
Intervention: Ramipril 10 mg
Number of subjects: 812
Study: 15291653

Group type: EXPERIMENTAL
Intervention: Coadministration of fluvoxamine (50 mg/day) plus low-dose clozapine (≤ 250 mg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Monotherapy with clozapine (≤ 600 mg/day)
Number of subjects: 68
Study: 11412167

Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 22

Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 22
Study: 9415855

Group type: EXPERIMENTAL
Intervention: Psychological stress (mental arithmetic)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Males
Number of subjects: 75

Group type: COMPARATOR
Intervention: Females
Number of subjects: 75
Study: 8429114

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg, four times daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg, twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enoxacin alone
Number of subjects: 10
Study: 31677703

Group type: EXPERIMENTAL
Intervention: Saffron (15 mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29247154

Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) 2 mg/kg administered intravenously at weeks 0, 4, 12, and every 8 weeks
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) 2 mg/kg administered intravenously
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo (PBO) administered intravenously
Number of subjects: 208
Study: 26391697

Group type: EXPERIMENTAL
Intervention: Preservative-free fixed-dose combination (FDC) of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost 0.0015%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Preservative-free timolol 0.5%
Number of subjects: 15
Study: 24524229

Group type: EXPERIMENTAL
Intervention: Full PopART combination HIV prevention package including annual home-based HIV testing, promotion of medical male circumcision for HIV-negative men, and offer of immediate ART for those testing HIV-positive
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Full package except that ART initiation will follow current national guidelines
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2500
Study: 22296864

Group type: EXPERIMENTAL
Intervention: DOX-STR
Number of subjects: 191

Group type: COMPARATOR
Intervention: DOX-RIF
Number of subjects: 191

Group type: COMPARATOR
Intervention: OFX-RIF
Number of subjects: 191
Study: 20309777

Group type: EXPERIMENTAL
Intervention: Volitional help sheet with explicit instructions to link occasions of temptation with behavioral responses
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group receiving a questionnaire and a volitional help sheet without explicit instructions
Number of subjects: 68
Study: 18057976

Group type: EXPERIMENTAL
Intervention: Low intense physical exercise in normobaric hypoxia (15 vol.% O2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low intense physical exercise in normobaric sham hypoxia (20.1 vol.% O2)
Number of subjects: 32
Study: 15837835

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 or 25 mg orally for 2 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (dosage not specified, orally for 2 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 12478352

Group type: EXPERIMENTAL
Intervention: DD genotype of ACE gene in VUR patients with renal scarring (44%)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: D allele frequency in VUR patients with scarred kidneys (0.64)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: I allele frequency in VUR patients with scarred kidneys (0.36)
Number of subjects: 77
Study: 10073373

Group type: EXPERIMENTAL
Intervention: Utility analysis among patients with schizophrenia
Number of subjects: 0
Study: 7538244

Group type: EXPERIMENTAL
Intervention: LN-SV-TPP
Number of subjects: 22

Group type: COMPARATOR
Intervention: RRP
Number of subjects: 22
Study: 2288297

Group type: EXPERIMENTAL
Intervention: YN-72 30 mg/day
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: YN-72 150 mg/day
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: YN-72 300 mg/day
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 7191314

Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 64
Study: 30691157

Group type: EXPERIMENTAL
Intervention: Twin Track Socio-Economic Development (SED) intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: SED clients
Number of subjects: 87
Study: 27752075

Group type: EXPERIMENTAL
Intervention: High-dose folinic acid (2 mg kg-1 per day, maximum 50 mg per day; n=23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 48
Study: 26966984

Group type: EXPERIMENTAL
Intervention: Card game 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Card game 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Card game 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Card game 4
Number of subjects: 0
Study: 24649525

Group type: EXPERIMENTAL
Intervention: Lactic acid monitoring with target < 2 mmol/L
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Lactic acid monitoring
Number of subjects: 57
Study: 22727138

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT; V.A.C.® Therapy; KCI USA, Inc.)
Number of subjects: 0
Study: 21284136

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16908126

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 15741820

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 303

Group type: COMPARATOR
Intervention: Brimonidine tartrate 0.2% twice daily
Number of subjects: 303

Group type: COMPARATOR
Intervention: Comparison of latanoprost vs brimonidine
Number of subjects: 303

Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 303
Study: 14507154

Group type: EXPERIMENTAL
Intervention: Various treatment approaches for fixation of mandibular fractures
Number of subjects: 834

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 834
Study: 9445241

Group type: EXPERIMENTAL
Intervention: Satigrel
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 9
Study: 7875025

Group type: EXPERIMENTAL
Intervention: Group A: Ondansetron 8 mg IV infusion before CDDP, followed by 8 mg tablets in the afternoon and before sleeping on the first day, then 3 tablets of 8 mg daily for the next 3 days.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B: Ondansetron 8 mg IV infusion on the first day, followed by the same regimen as Group A.
Number of subjects: 90
Study: 2151197

Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg to 16 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol 50 mg to 100 mg once daily
Number of subjects: 40
Study: 365801

Group type: EXPERIMENTAL
Intervention: Indomethacin combined with sodium salicylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 0
Study: 31370950

Group type: EXPERIMENTAL
Intervention: Age ≤55 years
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Age ≥85 years
Number of subjects: 10
Study: 29315129

Group type: EXPERIMENTAL
Intervention: Adductor canal block with 30 mL of ropivacaine 0.5% with 1:400,000 epinephrine
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Adductor canal block with active drug and 100 μg of ITM
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sham adductor canal block with 30 mL of normal saline
Number of subjects: 201
Study: 27187300

Group type: EXPERIMENTAL
Intervention: rhEPO (3000 IU/kg)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo (isotonic saline, 0.9%)
Number of subjects: 448
Study: 24568228

Group type: EXPERIMENTAL
Intervention: Web-based modules (10 modules over 4 weeks)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 164
Study: 22386051

Group type: EXPERIMENTAL
Intervention: Home-use nonablative fractional laser device (daily treatments during active phase, twice-weekly during maintenance phase)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Home-use nonablative fractional laser device (twice-weekly treatments during maintenance phase)
Number of subjects: 124
Study: 20068422

Group type: EXPERIMENTAL
Intervention: 8 weeks' exercise training
Number of subjects: 49
Study: 17290311

Group type: EXPERIMENTAL
Intervention: Structured lung sport programme for 12 months
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (no sport)
Number of subjects: 7
Study: 16051712

Group type: EXPERIMENTAL
Intervention: Resistance loading (RL) of knee extensors
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Resistance loading (RL) in older adults
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Resistance loading (RL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Baseline levels in older females vs young females
Number of subjects: 38
Study: 12942250

Group type: EXPERIMENTAL
Intervention: Octenidine dihydrochloride, phenoxyethanol (nonspecific mucosal antiseptic)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Clotrimazole (specific topical antifungal agent)
Number of subjects: 491
Study: 10397513

Group type: EXPERIMENTAL
Intervention: Initial periodontal therapy and gingival curettage
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions only)
Number of subjects: 31
Study: 8893679

Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 116
Study: 1387475

Group type: EXPERIMENTAL
Intervention: Amlodipine (single dose)
Number of subjects: 16
Study: 6381003

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 8
Study: 31219404

Group type: EXPERIMENTAL
Intervention: Ego-depletion (experimental) group (n=26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-ego-depletion (control) group (n=25)
Number of subjects: 51
Study: 28714180

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.i.d.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 25945764

Group type: EXPERIMENTAL
Intervention: Topical sodium fluoride (SF) 0.11%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo gel (PG)
Number of subjects: 32
Study: 24378865

Group type: EXPERIMENTAL
Intervention: Self-triage kiosk group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard nurse triage group
Number of subjects: 200
Study: 21129822

Group type: EXPERIMENTAL
Intervention: Single-use metal laryngoscope blades
Number of subjects: 817

Group type: COMPARATOR
Intervention: Reusable metal laryngoscope blades
Number of subjects: 817
Study: 19719736

Group type: EXPERIMENTAL
Intervention: Submerged implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-submerged implants
Number of subjects: 30
Study: 17402869

Group type: EXPERIMENTAL
Intervention: Peer-led interactive program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard program
Number of subjects: 16
Study: 15072249

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting filter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control filter
Number of subjects: 50
Study: 12828139

Group type: EXPERIMENTAL
Intervention: Anesthetic gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 85
Study: 9821908

Group type: EXPERIMENTAL
Intervention: Neck collar (intervention group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No neck collar (control group)
Number of subjects: 15
Study: 8027158

Group type: EXPERIMENTAL
Intervention: Proprioception enhancement programme (P)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Muscle strengthening programme (T)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (P and T)
Number of subjects: 50
Study: 2547028

Group type: COMPARATOR
Intervention: Cisplatin (120 mg/m2)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (100 mg/m2 on days 1, 2, and 3)
Number of subjects: 162
Study: 192510

Group type: EXPERIMENTAL
Intervention: Practolol (100 mg, three times daily)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol (0-20 microng/min after placebo; 0-80 microng/min after practolol)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0-20 microng/min in the placebo phase; 0-16 microng/min in the practolol phase)
Number of subjects: 7
Study: 31776880

Group type: EXPERIMENTAL
Intervention: Hydrocelectomy with excision of the sac using LigaSure™ device
Number of subjects: 82

Group type: COMPARATOR
Intervention: Jaboulay's technique
Number of subjects: 82
Study: 30341058

Group type: EXPERIMENTAL
Intervention: Preemptive nucleos(t)ide analog treatment (NAT)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Prophylactic nucleos(t)ide analog treatment (NAT)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: HBV DNA monitoring-guided preemptive NAT
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Prophylactic NAT
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Detectable HBV DNA at baseline
Number of subjects: 326
Study: 29093506

Group type: EXPERIMENTAL
Intervention: Interaction Factor (IF) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stochastic modelling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analytical relationship between IF and overlap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ImageJ plugin for IF determination
Number of subjects: 0
Study: 26005166

Group type: EXPERIMENTAL
Intervention: Brief nursing intervention to detect cognitive and emotional problems, provide information and support, promote self‐management, and refer to specialised care
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Brief nursing intervention
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 185
Study: 25910292

Group type: EXPERIMENTAL
Intervention: Hepatitis C with steatosis + NAFLD (Group 2)
Number of subjects: 405

Group type: COMPARATOR
Intervention: IBD + dyspepsia + hepatitis C without steatosis (Group 1)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Group with fatty liver
Number of subjects: 405

Group type: COMPARATOR
Intervention: Group without fatty liver
Number of subjects: 405